Figure 3.
Validation of CLT expression prevalence. (A) Percentage of CLTs expressed in each bin of percentage of positive samples in larger cohorts of primary SKCM (n = 77), metastatic SKCM (SKCM_m; n = 318), or UVM (n = 31). (B) Number and overlap between melanoma types of CLTs that were validated in the larger cohorts, that is, expressed in >25% of cancer patient samples in the validation cohort. (C) Percentage of CLTs expressed in each bin of percentage of positive samples in larger cohorts of LUAD (n = 395) or LUSC (n = 338). Samples were considered positive if transcript expression level was more than three times that of the highest median in any normal tissue.
